When most investors think about biotechnology, they naturally focus on the industry’s biggest names. Larger companies often have deeper research budgets, global operations, established commercial teams, and the financial resources to fund years of clinical development.
It seems reasonable to assume that the most important medical breakthroughs and the most significant regulatory milestones would come from those organizations.
Biotechnology, however, has never worked quite that way.
Some of the industry’s most important innovations have originated from companies that were relatively small when their therapies first began attracting regulatory attention. That’s because the U.S. Food and Drug Administration doesn’t evaluate a treatment based on the size of the company developing it. It evaluates the science, the seriousness of the disease being treated, and whether patients have meaningful unmet medical needs.
That distinction can create opportunities for investors willing to look beyond market capitalization.
One recent example is Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage biotechnology company that recently received Fast Track designation from the FDA for its investigational immunotherapy, pelareorep, in combination with a checkpoint inhibitor for patients with second-line and later squamous cell carcinoma of the anal canal (SCAC).
At first glance, Fast Track designation can sound like another regulatory headline. In reality, it represents something more meaningful.
The FDA grants Fast Track status to therapies intended to treat serious conditions when early evidence suggests they may address significant unmet medical needs. The designation does not guarantee approval, nor does it lower the standards required for demonstrating safety and effectiveness. Instead, it allows closer interaction between the FDA and the company throughout development, creating opportunities for more frequent guidance, rolling review of certain application sections, and potentially a more efficient regulatory process.
For investors following emerging biotechnology companies, those distinctions matter.
Unlike mature pharmaceutical companies that are often evaluated on revenue growth and earnings, clinical-stage biotechnology companies are frequently valued based on their ability to successfully advance promising therapies through clinical development and regulatory review. Regulatory milestones such as Fast Track designation can therefore provide insight into how development programs are progressing long before a product reaches the market.
In Oncolytics’ case, the designation followed encouraging findings from the company’s ongoing GOBLET study evaluating pelareorep in combination with atezolizumab for advanced anal cancer. The combination produced an objective response rate of approximately 30%, while responding patients experienced a median duration of response of approximately 15.5 months.
The study also reported a 12-month overall survival rate of 82%, comparing favorably with historical experience reported for this difficult-to-treat patient population. Although these findings will require confirmation in larger studies, they provided sufficient support for continued regulatory engagement.
More broadly, the announcement highlights an important trend across biotechnology.
Success is no longer measured solely by discovering an innovative therapy. Investors are increasingly evaluating whether management teams can execute across every stage of development—from designing clinical trials and enrolling patients to navigating regulatory pathways and preparing for potential commercialization. Scientific innovation remains the foundation, but disciplined execution is becoming an equally important part of the investment story.
This helps explain why smaller biotechnology companies can occasionally command significant attention despite operating with far fewer resources than industry leaders. Their value is often tied less to size than to the quality of their science, the strength of their clinical data, and their ability to move efficiently through the regulatory process.
That doesn’t mean every promising therapy will ultimately reach the market. Drug development remains one of the most challenging and uncertain industries in the world, and most investigational medicines will require years of additional testing before any regulatory approval is possible.
Even so, investors who focus only on company size may overlook where some of biotechnology’s earliest opportunities begin.
Large pharmaceutical companies will continue to play a dominant role in bringing medicines to patients around the world. Yet many of tomorrow’s innovations will likely originate much earlier, inside companies that are still building their clinical evidence one study at a time.
The recent Fast Track designation awarded to Oncolytics Biotech serves as a timely reminder of that reality. In biotechnology, the next important development isn’t always announced by the largest company in the room. Sometimes it comes from a smaller innovator whose science has earned the attention of regulators—and, increasingly, the attention of investors as well.
